We Work For Health Washington Partners

Co-Chairs

• Bob Drewel, Executive Director, Puget Sound Regional Council
• Dr. Elson S. Floyd, President, Washington State University
• Chris Rivera, President, Washington Biotechnology and Biomedical Association
• Rogers Weed, Director, Washington State Department of Community, Trade and Economic Development
• Dr. Lee Huntsman, Executive Director, Life Sciences Discovery Fund; President Emeritus, University of Washington

Business/Economic Development/Biopharmaceutical Partners

• Amgen Inc., Tim Martin, Director of State Government Relations
• Association of Washington Business, Don Brunell, President
• Bayer Inc., Jim Hoover, Senior Regional Manager of State Government Affairs
• The Blume Company, Bruce Blume, Chairman and CEO
• CG Therapeutics Inc., Denise M. Harrison, President & CEO
• Downtown Seattle Association, Kate Joncas, President
• Economic Development Board of Tacoma-Pierce County, Bruce Kendall, CEO
• Enterprise Seattle, Jeff Marcell, Executive Vice President
• Greater Seattle Chamber of Commerce, George Allen, Senior Vice President, Government Relations
• Greater Seattle Chamber of Commerce, Tayloe Washburn, Chair of the Board
• King County Business Relations and Economic Development, George Northcroft, Director
• Office of Governor Chris Gregoire, Marc Baldwin, Senior Policy Advisor
• PhRMA
• Seattle-Northwest Securities, Maud Daudon, CEO
• Snohomish County Economic Development Council, Deborah Knutson, President
• Vulcan Inc., Lyn Tangen, Director of Community and Government Relations
• Washington Roundtable, Steven Mullin, President

Health Advocacy Groups

• PATH, John Wecker, Ph.D., Global Program Leader Immunization Solutions
• Washington Global Health Alliance, Lisa Cohen, Director

Research and Academic Institutions

• Allen Institute for Brain Science, Elaine Jones, Chief Operating Officer
• Seattle Biomedical Research Institute, Michael Podlin, Vice President - Institutional Advancement
• Washington Research Council, Al Ralston, President
• Washington State University, John Gardner, Ph.D., Vice President for Economic Development & Global Engagement

Industry Impact

America’s biopharmaceutical sector helps to research, manufacture, distribute and promote innovative therapies that make a critical difference in the lives of millions of people. In the last ten years, scientists have discovered and developed more than 300 completely new medicines, vaccines and biologics approved by FDA.

The value of this sector, however, extends beyond life-enhancing advancements in medicine and includes great contributions to our national and state economies. As vital economic partners, biopharmaceutical companies generate tax revenue, create high-paying jobs and provide growth opportunities for related industries and domestic labor. In fact:

• The industry provides jobs in all 50 states, Washington, D.C., and Puerto Rico. States in which the national biopharmaceutical sector supported the largest number of jobs in 2006 included: California, New York, New Jersey, Pennsylvania, and Illinois.
• The industry directly provided 686,422 jobs in 2006 and supported an estimated 3.2 million jobs across the U.S. economy when accounting its full ripple effect (i.e., direct, indirect, and induced jobs).
• The industry’s direct contribution to the GDP in 2006, $88.5 billion, was triple the average contribution from sectors in the rest of the economy. For every dollar the industry contributed to the GDP in 2006, the ripple effect of that activity supported another $2.33 in contribution to the GDP from other sectors.
• In 2006, U.S. Biopharmaceutical companies invested $56.1 billion in research and development for new medicines.

In addition, many biopharmaceutical companies provide philanthropic assistance in their local communities through support of access to affordable products, education, social services, arts and other community needs.

The biopharmaceutical sector is creating the momentum to protect and foster innovation and scientific discovery. These groups are working together to continue advancements in medical innovation and ensure its future in the United States. They recognize the value of our country’s ability to innovate and are taking steps to preserve America’s leadership in order to remain competitive in the global environment.

The biopharmaceutical sector is committed to helping Americans lead longer, healthier lives and are steadfastly working to strengthen the economy.

To learn more, download the following report: The Biopharmaceutical Sector’s Impact on the U.S. Economy: Analysis at the National, State, and Local Levels by Archstone Consulting